191 related articles for article (PubMed ID: 32306562)
21. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
22. Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer.
Huo J; Wu L; Zang Y
J Immunol Res; 2021; 2021():5554342. PubMed ID: 34007851
[TBL] [Abstract][Full Text] [Related]
23. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
24. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
25. TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer.
Xiang K; Zhang M; Yang B; Liu X; Wang Y; Liu H; Song Y; Yuan Y; Zhang L; Wen T; Zhang GW
Int Immunopharmacol; 2024 Jun; 134():112224. PubMed ID: 38723370
[TBL] [Abstract][Full Text] [Related]
26. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
27. Key Genes Associated with Prognosis and Tumor Infiltrating Immune Cells in Gastric Cancer Patients Identified by Cross-Database Analysis.
Zhang T; Wang BF; Wang XY; Xiang L; Zheng P; Li HY; Tao PX; Wang DF; Gu BH; Chen H
Cancer Biother Radiopharm; 2020 Nov; 35(9):696-710. PubMed ID: 32401038
[No Abstract] [Full Text] [Related]
28. Combined Evaluation of Expression of CXCR4 and Nrf2 as Prognostic Factor for Patients with Gastric Carcinoma.
Yu S; Wu T; Wang J; Cheng C; Wang J; Sun L; Liu C; Cao G; Hu T
Anticancer Agents Med Chem; 2018; 18(3):388-393. PubMed ID: 29110625
[TBL] [Abstract][Full Text] [Related]
29. Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.
Amara S; Chaar I; Khiari M; Ounissi D; Weslati M; Boughriba R; Hmida AB; Bouraoui S
Cancer Biomark; 2015; 15(6):869-79. PubMed ID: 26406413
[TBL] [Abstract][Full Text] [Related]
30. [Effect of chemokine stromal cell derived factor-1 and its receptor CXCR4 on the peritoneal carcinometastasis of gastric cancer].
Ding YL; Zhang JL; Tang SF; Fu QY; Li ZT
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(3):202-5. PubMed ID: 18361822
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.
Chen T; Yang C; Dou R; Xiong B
Cancer Med; 2021 Sep; 10(18):6546-6560. PubMed ID: 34382341
[TBL] [Abstract][Full Text] [Related]
32.
Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
[TBL] [Abstract][Full Text] [Related]
33. CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in gastric cancer.
Arigami T; Natsugoe S; Uenosono Y; Yanagita S; Arima H; Hirata M; Ishigami S; Aikou T
Int J Oncol; 2009 Jul; 35(1):19-24. PubMed ID: 19513547
[TBL] [Abstract][Full Text] [Related]
34. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
35. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
[TBL] [Abstract][Full Text] [Related]
36. Identification of N7-methylguanosine related subtypes and construction of prognostic model in gastric cancer.
Li X; Dong H; Chen L; Wang Y; Hao Z; Zhang Y; Jiao Y; Zhao Z; Peng X; Zhan X
Front Immunol; 2022; 13():984149. PubMed ID: 36300121
[TBL] [Abstract][Full Text] [Related]
37. Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients.
Sun T; Wang D; Ping Y; Sang Y; Dai Y; Wang Y; Liu Z; Duan X; Tao Z; Liu W
Int J Oncol; 2020 Feb; 56(2):460-469. PubMed ID: 31894266
[TBL] [Abstract][Full Text] [Related]
38. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
39. Identification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer.
Li W; Zhou K; Li M; Hu Q; Wei W; Liu L; Zhao Q
BMC Gastroenterol; 2022 Feb; 22(1):45. PubMed ID: 35123417
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]